Global Strategic Decision Support // We specialize in Win/Loss, Competitive Intelligence, Primary Research, Strategy Workshops, and Trade Show Intelligence.
We'll be at @PharmaCIConf in Zurich between June 22-23. There is still time to register and join us in less than a month. We're looking forward to seeing you all there!
pharmaciconference.com/europ…
Our CEO @ErikGlitman will be participating in the @SCIP Foundations of Win/Loss training and certification workshop beginning tomorrow (5/17) at 10am EST through 5/19. A few seats are still available for you to join us! scip.org/page/Foundations-of…
That's a wrap on #IntelliCon2022! Thank you to all of the sponsors, speakers and attendees who joined us this year for #IntelliCon2022! We had a great time connecting this week and are already ready for next year's event!
We'll be at @SCIP IntelliCon next week starting on April 25th-27th in Minneapolis. If your company is attending and has an upcoming CI project that needs support, please reach out to info@fletchercsi.com and we can set up time for an introduction. bit.ly/3MePa4C
We're excited to officially offer our proprietary Win/Loss platform, LiveInsights, to all our current and future clients. This tool delivers real time access to project deliverables, process updates, and a best-in-class data analysis. fcsiwinloss.com/winloss_spla…
If you missed our webinar on Building Competitive Tracking Systems with @contify and @SCIP -- worry no more. You can watch the entire presentation here: bit.ly/3ceeTeb
Save the Date: Join us, @contify, & @SCIP May 12th, for a live webinar on Building Competitive Tracking Systems Based on Scenario Planning. More details to follow! #webinar#competitiveintelligence
Save the Date: Join us, @contify, & @SCIP May 12th, for a live webinar on Building Competitive Tracking Systems Based on Scenario Planning. More details to follow! #webinar#competitiveintelligence
Check out this FWPharma article : Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis. firstwordpharma.com/node/181…
Check out this FWPharma article : Health Canada has initiated a safety review on Xeljanz and Xeljanz XR (tofacitinib), used to treat arthritis and ulcerative colitis. firstwordpharma.com/node/181…